TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30797084
Drug: Dalbavancin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin 1000 mg followed by 500 mg a week later (two doses)
Study: 27632267
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading with two Straumann implants splinted with a Dolder bar, loaded within 48 hours postoperative.
Study: 27632267
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading with two Straumann implants, loaded 6 weeks postoperative.
Study: 1425713
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/12 h)
Study: 18689384
Drug: High-dose potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose potassium citrate (55.5 mEq/d)
Study: 18689384
Drug: Low-dose potassium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose potassium citrate (18.5 mEq/d)
Study: 18689384
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g additional fruit and vegetables/d (equivalent of 18.5 mEq alkali)
Study: 15932387
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with 100 IR grass pollen extract
Study: 15932387
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with 300 IR grass pollen extract
Study: 10350223
Drug: Zafirlukast, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast, a cysteinyl leukotriene receptor antagonist, administered for 14 days
Study: 8607661
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg bolus over 2 minutes followed by a 30-minute infusion of 0.375 mg/min and then 0.125 mg/min for 3 days)
Study: 1836595
Drug: Daily plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily plasma exchanges with fresh frozen plasma (15 ml/kg) in albumin (45 ml/kg)
Study: 1836595
Drug: Daily transfusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily transfusions of fresh frozen plasma (15 ml/kg)
Study: 6429905
Drug: Monthly supervision
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly supervision of CBD family planning programs
Study: 15624267
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg/day plus MPA 1.25 mg/day (Group B)
Study: 15624267
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/day plus MPA 2.5 mg/day (Group A)
Study: 2951827
Drug: Ipratropium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium 0.5 mg/fenoterol 1.25 mg
Study: 2951827
Drug: Ipratropium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium 0.5 mg/fenoterol 2.5 mg
Study: 2951827
Drug: Ipratropium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium 0.5 mg/fenoterol 5.0 mg
Study: 2951827
Drug: Salbutamol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 5.0 mg
Study: 27023345
Drug: Antenatal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal exercise programme (weekly classes from the 20th week of pregnancy)
Study: 23062413
Drug: Low preoperative
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low preoperative urine hepcidin concentration (median, 15.3 ng/mL)
Study: 23062413
Drug: Low preoperative
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low preoperative plasma hepcidin concentration (median, 49.2 ng/mL)
Study: 14768770
Drug: Glimepiride (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1, 2, 3, 4 or 6 mg once daily, n = 111)
Study: 14768770
Drug: Acarbose (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50, 100, 150 or 200 mg 3 times daily, n = 108)
Study: 10720032
Drug: High-dose adrenomedullin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenomedullin (5.8 pmol/kg x min)
Study: 10720032
Drug: Low-dose adrenomedullin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adrenomedullin (2.9 pmol/kg x min)
Study: 9022839
Drug: Weight training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight training program (upper and lower body exercises, twice per week for 20 weeks)
Study: 4079669
Drug: Modified amino
Normalized name: LYSYL-PEG-LAUROYL-MODIFIED AMINO ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified amino acid solution enriched in branched-chain amino acids (BAA)
Study: 4079669
Drug: Conventional amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amino acid solution (Azonutril)
Study: 26774152
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy combined with intraperitoneal hyperthermic chemoperfusion
Study: 26774152
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only systemic chemotherapy)
Study: 24400998
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) - 559.2 mg total catechins, 120.4 mg caffeine
Study: 22997793
Drug: Ultrastructural acupotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrastructural acupotomy therapy at the counter‐Ashi points, treatment given once a week for 1 month.
Study: 22997793
Drug: Conventional acupuncture‐moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture‐moxibustion therapy, treatment given once daily for 1 month.
Study: 15363881
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral self-help treatment
Study: 15363881
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after treatment termination
Study: 11288822
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10-40 mg/day)
Study: 11288822
Drug: Hydrochlorothiazide alone
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide alone or in combination
Study: 11288822
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with nitrendipine
Study: 9625908
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (loading dose of 3.2 mg/kg, followed by 1.6 mg/kg daily for 4 days)
Study: 9625908
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine (loading dose of 20 mg/kg, followed by 10 mg/kg every 8 h for at least 48 h, then oral quinine for a total of 7 days)
Study: 7955999
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and oral hypoglycaemic agents (Group 2)
Study: 26706833
Drug: Exemestane +
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane + Metformin
Study: 26706833
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (Tamoxifen followed by Exemestane)
Study: 16336883
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% cream on both sides of the face
Study: 16336883
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% cream on one side of the face
Study: 16336883
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream on both sides of the face
Study: 1887750
Drug: Famotidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (0.5 mg.kg-1 per dose, two doses)
Study: 1887750
Drug: Famotidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (0.5 mg.kg-1 per dose, one dose)
Study: 1887750
Drug: Famotidine (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (one dose) and Placebo (one dose)
Study: 1887750
Drug: Famotidine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (any dose)
Study: 30221589
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioural therapy (TCBT)
Study: 30221589
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behavioural therapy (CBT)
Study: 28941657
Drug: Complex rehabilitation
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex rehabilitation combined with complex decongestive therapy (CRCDT)
Study: 15107413
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplement (0.1 g/kg) given four times daily for the first 14 days
Study: 11059859
Drug: Prednisolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (50 mg/day)
Study: 8096956
Drug: Halofantrine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (24 mg/kg)
Study: 8096956
Drug: Halofantrine (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (72 mg/kg, 8 mg/kg every 8 h for 3 days)
Study: 8096956
Drug: Halofantrine (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (72 mg/kg)
Study: 8096956
Drug: High-dose Halofantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Halofantrine (72 mg/kg)
Study: 4036539
Drug: Atropine 0.03
Normalized name: atropine 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.03 mg/kg p.o.
Study: 4036539
Drug: Atropine 0.02
Normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.02 mg/kg i.m.
Study: 2833543
Drug: Fluvoxamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150 mg daily for 6 weeks)
Study: 2833543
Drug: Maprotiline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (150 mg daily for 6 weeks)
Study: 25520426
Drug: PrEP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (daily oral combination tenofovir disoproxil fumarate plus emtricitabine)
Study: 21389754
Drug: STEPPS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEPPS plus adjunctive individual therapy
Study: 18991076
Drug: CEE/MPA (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (1.25 or 2.5 mg/day)
Study: 18991076
Drug: Tibolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (1.25 or 2.5 mg/day)
Study: 12843685
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (group B)
Study: 12843685
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem (group A)
Study: 12843685
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drugs (group C)
Study: 11938827
Drug: 912 compound
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 912 compound (Chinese herbal preparation)
Study: 8226711
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate 60 mg twice a day (Group 1)
Study: 8226711
Drug: Ferric polymaltose
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric polymaltose 100 mg daily (Group 2)
Study: 8226711
Drug: Ferric polymaltose
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric polymaltose 100 mg twice a day (Group 3)
Study: 25666686
Drug: Rusovastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rusovastatin 40 mg
Study: 18359360
Drug: Memantine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (up to 20 mg for 90 days)
Study: 3530367
Drug: H/DHE (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H/DHE (heparin sodium 5000 units plus dihydroergotamine mesylate 0.5 mg, twice a day)
Study: 3530367
Drug: LMWH/DHE (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH/DHE (low molecular weight heparin 1500 units plus dihydroergotamine mesylate 0.5 mg, once a day)
Study: 19294863
Drug: Zhizhuwan (ZZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhuwan (ZZ) 90 g per day for 1 month
Study: 19294863
Drug: Cisapride 30
Normalized name: cisapride 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 30 mg per day for 1 month
Study: 1930916
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (Catapres‐TTS)
Study: 19622627
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (1.0 mg/m² . d)
Study: 15605000
Drug: 15 to
Normalized name: ointment base no.215 TOPICAL OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 to 25 mL injection of 1:10,000 solution of epinephrine
Study: 15605000
Drug: 35 to
Normalized name: Hydro 35 Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 to 45 mL injection of 1:10,000 solution of epinephrine
Study: 15605000
Drug: 35 to
Normalized name: Hydro 35 Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 to 45 mL injection of 1:10,000 solution of epinephrine for gastric body ulcers
Study: 15605000
Drug: 15 to
Normalized name: ointment base no.215 TOPICAL OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 to 25 mL injection of 1:10,000 solution of epinephrine for gastric body ulcers
Study: 9138173
Drug: Cremophor EL-solubilized
Normalized name: hydroxypropyl cellulose (type EL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor EL-solubilized preparation of vitamin K1 (Konakion drops)
Study: 9138173
Drug: Mixed-micellar preparation
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-micellar preparation of vitamin K1 (Konakion MM)
Study: 2083195
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg plus amiloride 5 mg (HA)
Study: 2083195
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg twice daily (F)
Study: 2083195
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 10 mg daily (FER)
Study: 22190065
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg b.i.d. for 5 days)
Study: 20081560
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for spinal stenosis
Study: 20081560
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for spinal stenosis with degenerative spondylolisthesis
Study: 11994341
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g strontium ranelate per day
Study: 11994341
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g strontium ranelate per day
Study: 11994341
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g strontium ranelate per day
Study: 10366258
Drug: Reinforcing Kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcing Kidney and Invigorating Spleen Principle (RKISP) with steroid aerosol
Study: 10366258
Drug: Steroid aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid aerosol
Study: 15278814
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch applied for 15 min (Group A)
Study: 15278814
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch applied for 30 min (Group B)
Study: 2958035
Drug: P-contrast (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-contrast (1 g/cm3)
Study: 2958035
Drug: Barium (Mixobar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium (Mixobar Ventrikel 400 mg/ml)
Study: 31022311
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of mitomycin-C (MMC)
Study: 31022311
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of saline (placebo)
Study: 23029716
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg orally, three times a day for 4 weeks
Study: 20460237
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (6+/‐2 mg/kg)
Study: 20460237
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (15+/‐2 mg/kg)
Study: 20460237
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (24+/‐2 mg/kg)
Study: 20460237
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (34+/‐2 mg/kg)
Study: 10419812
Drug: Localization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localization of the AT(1) receptor using immunocytochemistry; expression of prorenin, angiotensinogen, and AT(1) receptor mRNA using RT-PCR.
Study: 7556823
Drug: Intermittent injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent injections (CIT)
Study: 1763599
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg alfentanil
Study: 7073148
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin prophylaxis (5000 U twice daily)
Study: 31781682
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus (0.5 mg on alternate days for 24 weeks) combined with conventional glucocorticoids and immunosuppressants
Study: 31781682
Drug: Conventional glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucocorticoids and immunosuppressants
Study: 17113170
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg once daily for 3-6 weeks, followed by 16 mg once daily for 6 months
Study: 15066944
Drug: Phenylpropanolamine, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine, 12.5 to 25 mg PO with 16 oz of water
Study: 15066944
Drug: Phenylpropanolamine, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine, 12.5 to 25 mg PO
Study: 15066944
Drug: Pseudoephedrine, 30
Normalized name: Dextromethorphan/Guaifenesin/Pseudoephedrine, 30 mg-600 mg-60 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine, 30 mg PO with 16 oz of water
Study: 10921031
Drug: ATRA (10(-6)
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA (10(-6) mmol/L)
Study: 8080349
Drug: Buspirone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone therapy
Study: 2685709
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (Healon) injection (0.50 to 0.75 ml)
Study: 2685709
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sodium hyaluronate injection)
Study: 1272686
Drug: Sedative medications
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative medications
Study: 21851368
Drug: L‐MTAD group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐MTAD group treated with laser irradiation plus a mixture of doxycycline, tetracycline isomer and citric acid
Study: 21851368
Drug: RC‐Prep group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC‐Prep group treated with EDTA gel or cream (RC‐Prep)
Study: 16254422
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus nitroglycerin and verapamil (Group A)
Study: 16254422
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus nitroglycerin (Group B)
Study: 10639039
Drug: SonoVue 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 0.03 mL/kg
Study: 10639039
Drug: SonoVue 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue 0.3 mL/kg
Study: 1587965
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg triamcinolone acetonide aerosol
Study: 1587965
Drug: 800 mcg
Normalized name: Biotin 800 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mcg triamcinolone acetonide aerosol
Study: 1587965
Drug: 1600 mcg
Normalized name: ACTIQ 1600 MCG Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mcg triamcinolone acetonide aerosol
Study: 4004963
Drug: Five health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five health status instruments administered before and after total joint arthroplasty
Study: 30773222
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2 weekly for up to six doses with 41.4-45 Gy external beam radiation therapy followed by high dose rate brachytherapy
Study: 29382797
Drug: GSK1995057 (nebulised
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1995057 (nebulised TNFR1 antagonist)
Study: 25837513
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccine
Study: 19415181
Drug: Temsirolimus 75
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 75 mg, administered orally once daily for 5 days every 2 weeks
Study: 15161787
Drug: rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (8 mg/day)